Liposomal small-molecule (lipid) nanotherapeutic

Class

Liposomal small-molecule (lipid) nanotherapeutic — C6 ceramide encapsulated in a nanoliposome

Pathway

Sphingolipid/ceramide-induced apoptosis (mitochondrial pathway)

Notes

original target text: Liposomal small-molecule (lipid) nanotherapeutic — C6 ceramide encapsulated in a nanoliposome

Ceramide is a lipid signaling molecule that, when it accumulates inside a cell, activates a self-destruct program called apoptosis, largely through effects on mitochondria. Many cancer cells shift their internal lipid chemistry to keep ceramide levels low and pro-survival lipids high, which helps them resist death signals from chemotherapy and other treatments. Supplying an exogenous form of ceramide can restore this pro-death signaling. Natural ceramide, however, is poorly soluble in blood and breaks down quickly, so it cannot be given directly as a drug. Encapsulating a short-chain ceramide analog (C6 ceramide) inside a nanoliposome — a small synthetic lipid vesicle — solves this delivery problem: it protects the ceramide from rapid breakdown, allows intravenous administration, and can take advantage of the leaky, disorganized blood vessels found in many tumors to accumulate preferentially in tumor tissue. The broad rationale for this class of mechanism is to bypass cancer cells' resistance to conventional apoptotic triggers by directly restocking a lipid that pushes mitochondria toward the cell-death pathway. This approach is relevant across oncology, particularly in cancers where sphingolipid metabolism is known to be skewed toward survival.